Clinical trials - Press Releases

Date	Title	Company
14-Jul-2022	Brits have worst mental health in Europe, STADA Health Report 2022 reveals	The STADA Group
14-Jul-2022	PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of AKL-T01 Product Candidate	PureTech Health plc
14-Jul-2022	TANIOBIS invests in new test and production plant for chlorides	TANIOBIS
14-Jul-2022	83% fewer vaccinated women hospitalised during pregnancy – but only Omicron jab can maintain success	New Office for National Statistics
14-Jul-2022	Nanoform and Pharmanovia to breathe new life into iconic medicines	Nanoform Finland Plc
14-Jul-2022	Grünenthal acquires testosterone treatment Nebido™ from Bayer	Bayer
14-Jul-2022	Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis	Sanofi
14-Jul-2022	Systemic Lupus Erythematosus Market accounted for US$ 1.87 billion in 2019 and is estimated to be US$ 3.6 billion by 2029 and is anticipated to register a CAGR of 7.0%	Prophecy Market Insights
13-Jul-2022	Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea	Novotech Health Holdings Pte Ltd
13-Jul-2022	PharmiWeb.Jobs Welcomes Excelya	PharmiWeb.Jobs
12-Jul-2022	Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa	Endogena Therapeutics
12-Jul-2022	No thromboembolic events or related serious adverse events reported over 12-week observation period in FRONTIER1 study.1	Novo Nordisk
12-Jul-2022	Data presented today show a reduction in treated spontaneous and traumatic bleeds and mean annualised bleeding rate (ABR) of 1.7 with concizumab1	Novo Nordisk
12-Jul-2022	Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis	Sanofi
12-Jul-2022	Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxis	Sanofi
08-Jul-2022	FDA Releases Draft Guidance on CMC For Individualized ASO Therapies	SAE Media Group
06-Jul-2022	Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007	HUTCHMED
04-Jul-2022	Innovative Trials acquires first US office as part of mission to support patient access to clinical trials	Innovative Trials
04-Jul-2022	CD Bioparticles Expands Lipid System Portfolio by the Launch of Sphingolipids	CD Bioparticles
04-Jul-2022	CD Bioparticles Announces the Launch of Colored Polystyrene Particles	CD Bioparticles